Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo

European Journal of Clinical Pharmacology

Volumn 55, Issue 5, 1999, Pages 375-382

  Larsen, J Teilmann ^a   Hansen, L Lindal ^a   Spigset, O ^b   Brosen K ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Drug interaction; Fluvoxamine; Tacrine

Indexed keywords

FLUVOXAMINE; FLUVOXAMINE MALEATE; TACRINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INTERACTION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIVER TOXICITY; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADULT; CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; DRUG INTERACTIONS; FLUVOXAMINE; HUMANS; MALE; SEROTONIN UPTAKE INHIBITORS; TACRINE;

EID: 0032859821     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050643     Document Type: Article

References (30)

1. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI (1994) A 30-week randomized controlled trail of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 271: 985-991
2. Ford JM, Truman CA, Wilcock GK, Roberts CJ (1993) Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clin Pharmacol Ther 53: 691-695
3. Ahlin A, Adem A, Junthe T, Ohman G, Nyback H (1992) Pharmacokinetics of tetrahydroaminoacridine: Relations to clinical and biochemical effects in Alzheimer patients. Int Clin Psychoparmacol 7: 129-136
4. O'Brien JT, Eagger S, Levy R (1991) Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer's disease. Age Ageing 20: 129-131
5. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW (1994) Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 271: 992-998
6. Hartvig P, Ashmark H, Aquilonius SM, Wiklund L, Lindstrom B (1990) Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine. Eur J Clin Pharmacol 38: 259-263
7. Forsyth DR, Wilcock GK, Morgan RA, Truman CA, Ford JM, Roberts CJ (1989) Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease. Clin Pharmacol Ther 46: 634-641
8. Hsu RS, DiLeo EM, Chesson SM (1990) High-performance liquid chromatography for the determination of tacrine and its metabolites in plasma. J Chromatogr 530: 170-176
9. Madden S, Spaldin V, Park BK (1995) Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 28: 449-457
10. Shutske GM, Pierrat FA, Kapples KJ, Cornfeldt ML, Szewczak MR, Huger FP, Bores GM, Haroutunian V, Davis KL (1989) 9-Amino-1,2,3,4-tetrahydroacridin-1-ols: Synthesis and evaluation as potential Alzheimer's disease therapeutics. J Med Chem 32: 1805-1813
11. Madden S, Woolf TF, Pool WF, Park BK (1993) An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem Pharmacol 46: 13-20
12. Spaldin V, Madden S, Adams DA, Edwards RJ, Davies DS, Park BK (1995) Determination of human hepatic cytochrome P4501A2 activity in vitro: Use of tacrine as an isoenzyme-specific probe. Drug Metab Dispos 23: 929-934
13. Woolf TF, Pool WF, Bjorge SM, et al (1993) Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference. Drug Metab Dispos 21: 874-882
14. Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, Watkins PB (1996) The caffeine breath test does not identify patients susceptible to tacrine hepatotoxity. Hepatology 23: 1429-1435
15. Spaldin V, Madden S, Pool WF, Woolf TF, Park BK (1994) The effect of enzyme inhibition on the metabolism and activation and tacrine by human liver microsomes. Br J Clin Pharmacol 38: 15-22
16. Brosen K, Skejelbo E, Rasmussen BB, Poulsen HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45: 1211-1214
17. Jeppesen U, Loft S, Poulsen HE, Brosen K (1996) A fluvoxamine-caffeine interaction study. Pharmacogenetics 6: 213-222
18. Rasmussen BB, Jeppesen U, Gaist D, Brosen K (1997) Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. Ther Drug Monit 19: 56-62
19. Hansen LL, Larsen JT, Brosen K (1998) Determination of tacrine and its metabolites in human plasma and urine by high-performance liquid chromatography and fluorescence detection. J Chromatogr B Biomed Sci Appl 712: 183-191
20. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R (1995) Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 58: 399-403
21. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI (1998) In vitro approaches to predicting drug interaction in vivo. Biochem Pharmacol 55: 113-122
22. Brosen K, Otton SV, Gram LF (1985) Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol (Copenh) 57: 357-360
23. Kukan M, Bezek S, Pool WF, Woolf TF (1994) Metabolic disposition of tacrine in primary suspensions of rat hepatocyte and in single-pass perfused liver: In vitro/in vivo comparisons. Xenobiotica 24: 1107-1117
24. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI (1995) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepresents. J Clin Psychopharmacol 15: 125-131
25. Becquemont L, Le Bot MA, Riche C, Beaune P (1996) Influence of fluvoxamine on tacrine metabolism in vitro: Potential implication for the hepatotoxity in vivo. Fundam Clin Pharmacol 10: 156-157
26. Davis KL, Powchik P (1995) Tacrine. Lancet 345: 625-630
27. Jeppesen U, Rasmussen BB, Brosen K (1997) Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 62: 279-286
28. von Moltke LL, Greenblatt DJ, Cotreau Bibbo MM, Harmatz JS, Shader RI (1994) Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38: 23-31
29. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K (1996) Dose-dependent inhibition of CYPIA2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51: 73-78
30. Becquemont L, Ragueneau I, Le Bot MA, Riche C, Funck Brentano C, Jaillon P (1997) Influence of the CYPIA2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 61: 619-627